Universal reference book for medicines
Product name: OKI

Active substance: ketoprofen

Type: NSAIDs

Manufacturer: DOMPE (Italy) manufactured by ISTITUTO de ANGELI (Italy)
Composition, form of production and packaging
Suppositories rectal (for children)
from white to light yellow color, torpedo-shaped.

1 supp.

ketoprofen lysine salt 60 mg

Excipients: semi-synthetic glycerides - 1020 mg.

5 pieces.
- Strips (2) - packs of cardboard.

Description of the drug approved by the manufacturer for the printed edition of 2016.


Has anti-inflammatory, analgesic and antipyretic effect. Inhibiting COX-1 and COX-2, inhibits the synthesis of prostaglandins. It has anti-bradykinin activity, stabilizes lysosomal membranes, and delays the release of enzymes that promote tissue destruction in chronic inflammation. Reduces the secretion of cytokines, inhibits the activity of neutrophils.
Reduces the morning stiffness and swelling of the joints, increases the volume of movements.

Ketoprofen lysine salt, in contrast to ketoprofen, is a quick-dissolving compound with a neutral pH and, as a result, almost does not irritate the gastrointestinal tract.



Ketoprofen lysine salt is rapidly absorbed: after rectal administration, the time to reach C max is 45-60 minutes.
The concentration in the plasma depends linearly on the dose taken.

Up to 99% of ketoprofen binds to plasma proteins, mainly with albumin.
V d is 0.1-0.2 l / kg. Easily penetrates through the histohematological barriers and is distributed in tissues and organs. Ketoprofen penetrates well into the synovial fluid and connective tissue. Although the concentration of ketoprofen in the synovial fluid is somewhat lower than in the plasma, it is more stable (lasts up to 30 hours).

Ketoprofen is mainly metabolized in the liver, where it undergoes glucuronization to form esters with glucuronic acid.


Metabolites are excreted mainly with urine (up to 76% within 24 hours).
The drug does not cumulate.

- short-term symptomatic treatment of inflammatory processes, accompanied by increased body temperature and painful sensations, incl.
with diseases of the musculoskeletal system and otitis;
- relief of postoperative pain.


Rectal to children aged 6 to 12 years (body weight over 30 kg) appoint 1 suppository for children (60 mg) 1-2 times / day.
Children over 12 years can be prescribed 1 suppository (60 mg) 3 times / day. The daily dose should not exceed 5 mg / kg of body weight.
The drug should not be used for more than 5 days without consulting a doctor.

Doses used to treat children do not have sufficient efficacy in the treatment of adults.


On the part of the hematopoiesis system: leukocytopenia, leukocytosis, lymphangitis, reduction of prothrombin time, thrombocytopenia, thrombocytopenic purpura, enlarged spleen, vasculitis.

From the side of the central nervous system: dizziness, hyperkinesia, tremor, vertigo, mood swings, anxiety, hallucinations, irritability, general malaise.

From the side of the organ of vision: conjunctivitis, impaired vision.

From the cardiovascular system: hypertension, hypotension, tachycardia, chest pain, syncopal conditions.

On the part of the respiratory system: bronchospasm, dyspnoea, sensation of spasm of the larynx, laryngospasm, laryngeal edema, rhinitis.

On the part of the digestive system: abdominal pain, diarrhea, stomatitis, esophagitis, gastritis, duodenitis, erosive and ulcerative gastrointestinal lesions, hematomasis, melena, increased bilirubin level, hepatic enzyme activity, hepatitis, hepatic insufficiency, liver enlargement.

From the urinary system: painful urination, cystitis, swelling, hematuria.

From the skin and subcutaneous tissues: erythematous exanthema, itching, maculopapular rash, increased sweating.

Allergic reactions: urticaria, angioedema, exudative erythema multiforme (including Stevens-Johnson syndrome), anaphylactoid reactions (edema of the oral mucosa, pharyngeal edema, periorbital edema).

Local reactions: burning, itching, heaviness in the anorectal area, exacerbation of hemorrhoids.

Other: disorder of the menstrual cycle, peripheral edema, pallor.


- "aspirin" asthma;

- Stomach ulcer and duodenal ulcer in the phase of exacerbation;

- ulcerative colitis in the phase of exacerbation;

- Crohn's disease;

- diverticulitis;

- peptic ulcer;

- Violations of blood clotting (including hemophilia);

- chronic renal failure;

- children's age till 6 years;

- Hypersensitivity to ketoprofen or other NSAIDs.

With caution should prescribe the drug for anemia, bronchial asthma, hyperbilirubinemia, liver failure, diabetes mellitus, dehydration, sepsis, chronic heart failure, edema, arterial hypertension, blood diseases (including leukopenia), a deficiency of glikozo-6-phosphate dehydrogenase, stomatitis.


The drug in forms for systemic use is contraindicated in the presence of severe impairment of kidney function.


At systemic application it is necessary to be cautious at an alcoholic cirrhosis of a liver, a hyperbilirubinemia, hepatic insufficiency.


The drug is contraindicated for children under 6 years.


During treatment with Oka, periodic monitoring of the peripheral blood picture and the functional state of the liver and kidneys is necessary.

If it is necessary to determine 17-ketosteroids, the drug should be discontinued 48 hours before the test.

Admission Oka can mask the signs of an infectious disease.

If the kidney and liver function is impaired, a dose reduction and careful monitoring is necessary.

The use of Oka in bronchial asthma can trigger an attack of suffocation.


At present, cases of Oka overdose have not been reported.


Inducers of microsomal oxidation in the liver (phenytoin, ethanol, barbiturates, flumecinol, rifampicin, phenylbutazone, tricyclic antidepressants) with simultaneous application with the Oca preparation increase the production of hydroxylated active metabolites.

Against the background of simultaneous application with the Oka drug, the effectiveness of uricosuric drugs decreases, the effect of anticoagulants, antiplatelet agents, fibrinolytic agents, ethanol, side effects of mineral corticoids, glucocorticoids, estrogens increases;
decreases the effectiveness of antihypertensive drugs and diuretics.
The simultaneous use of Oka with other NSAIDs, GCS, ethanol, corticotropin can lead to the formation of ulcers and the development of gastrointestinal bleeding, an increased risk of kidney dysfunction.

Simultaneous appointment of Oka with oral anticoagulants, heparin, thrombolytic agents, antiaggregants, cefoperazone, cefamandol and cefotetan increases the risk of bleeding.

Oak preparation with simultaneous application increases hypoglycemic action of insulin and oral hypoglycemic drugs (dose recalculation is necessary).

The combined use of Oka with sodium valproate causes disruption of platelet aggregation.

Ketoprofen with simultaneous application increases the concentration in the plasma of verapamil and nifedipine, lithium, methotrexate.

Antacids and colestyramine reduce the absorption of ketoprofen.


The drug is released by prescription.


The drug should be stored out of the reach of children at a temperature of no higher than 25 В° C.
Shelf life - 3 years.
Alphabetical index of medicines:
A  B  V  G  D  E  J
Z  I  Y  K  L  M  N
O  P  R  S  T  U  F
H  C  CH  SH  E  U  Y

Privacy policy:
Copyright 2009 - 2017. Universal reference book of medicines. All rights reserved.
When using site materials, an active hyperlink is required!